-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] Recently, Tongyi Pharmaceutical announced the completion of the B round of financi.
This round of financing was led by Huimei Capital, followed by Yuanfeng Capital, ABC International, Yicun Capital and other co-investors, and old shareholders Tong and Yucheng continued to inve.
Rai.
According to the announcement, the financing funds will be mainly used for the clinical development of Tongyi Bi-XDC pipeline, including CBP-1008 China key registration phase II clinical trial, CBP-1018 China-US clinical phase I/II trial, CBP-1019 China-US clinical trial Phase I clinical trials, CBP-8088 (C-PROTAC) Sino-US IND application, e.
The clinical advancement of multiple core pipelines marks the full-speed advancement of Tongyi Medicine's R&D pipeline in the dual-ligand drug coupling technology platform (Bi-XD.
It is understood that Tongyi Medicine has been committed to the research and development of tumor-targeted bispecific-Ligand Drug Conjugate (bi-XDC) innovative dru.
The financing funds will also be mainly used for the clinical development of Tongyi’s Bi-XDC pipeline, including CBP-1008 China’s pivotal registration phase II clinical trial, CBP-1018 China-US clinical phase I/II trial, and CBP-1019 China-US clinical phase I clinical tri.
Phase trial, CBP-8088 (C-PROTAC) Sino-US IND application,e.
The industry believes that the clinical advancement of multiple core pipelines indicates that Tongyi Medicine is advancing at full speed in the research and development pipeline of the dual-ligand drug coupling technology platform (Bi-XD.
In addition to Tongyi Medicine, in fact, before this, Suzhou Baimai Biopharmaceutical .
, L.
also announced the completion of the A round of financing exceeding 50 million yu.
This round of financing was exclusively invested by Linghang New Territori.
The proceeds from this financing will be used to promote the research and development and clinical trials of the company's tumor immunotherapy platform pipeline, as well as the construction of other platform technologies, while further improving the research and development team and expanding the research and development si.
In addition, Mozhuo Biological recently announced the completion of the A+ round of financing of nearly 100 million yu.
The funds raised in this round of financing will be mainly used to further expand the company's single-cell product research and development pipeli.
Since the beginning of this year, successful cases of investment and financing of pharmaceutical companies have continued to emerge in the indust.
According to incomplete statistics, there have been 161 cumulative investment and financing events on the innovative drug track in the first half of the ye.
Among them, 34 financing events focused on cell therapy, and 14 financing events exceeded 100 million yu.
Regarding the financing wave of innovative drug companies, the industry believes that this is mainly because most of the core products of innovative drug companies are still in the clinical or even preclinical research and development stage, and most of them have not yet formed a sizable and stable source of income, and need to obtain continuous cash through primary and secondary market financi.
due to fl.
In the past two years, the rapid influx of global funds into the biopharmaceutical industry has driven the sharp rise in the stock prices of pharmaceutical companies, and also led to continued active investment and financing activities in this fie.
Among them, it is worth noting that, from the perspective of innovative drugs, cell and gene therapy has clearly become a popular segment for investme.
However, it should be noted that although the investment opportunities in the field of medicine and health are still favored by the industry as a whole, the timing of the opening of the next financing window is still full of uncertainty, and many companies have begun to cut costs and put more Focus more on mature pipelin.
For example, Clover Bio will reduce its investment in non-COVID-19 related mid-to-late projects and new infrastructure in order to allocate resources to certain projec.
SCB313 (TRAIL trimer tumor project), SCB-808, SCB-420 (Fc fusion protein ) inputs to three projects have also been suspend.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
This round of financing was led by Huimei Capital, followed by Yuanfeng Capital, ABC International, Yicun Capital and other co-investors, and old shareholders Tong and Yucheng continued to inve.
Rai.
According to the announcement, the financing funds will be mainly used for the clinical development of Tongyi Bi-XDC pipeline, including CBP-1008 China key registration phase II clinical trial, CBP-1018 China-US clinical phase I/II trial, CBP-1019 China-US clinical trial Phase I clinical trials, CBP-8088 (C-PROTAC) Sino-US IND application, e.
The clinical advancement of multiple core pipelines marks the full-speed advancement of Tongyi Medicine's R&D pipeline in the dual-ligand drug coupling technology platform (Bi-XD.
It is understood that Tongyi Medicine has been committed to the research and development of tumor-targeted bispecific-Ligand Drug Conjugate (bi-XDC) innovative dru.
The financing funds will also be mainly used for the clinical development of Tongyi’s Bi-XDC pipeline, including CBP-1008 China’s pivotal registration phase II clinical trial, CBP-1018 China-US clinical phase I/II trial, and CBP-1019 China-US clinical phase I clinical tri.
Phase trial, CBP-8088 (C-PROTAC) Sino-US IND application,e.
The industry believes that the clinical advancement of multiple core pipelines indicates that Tongyi Medicine is advancing at full speed in the research and development pipeline of the dual-ligand drug coupling technology platform (Bi-XD.
In addition to Tongyi Medicine, in fact, before this, Suzhou Baimai Biopharmaceutical .
, L.
also announced the completion of the A round of financing exceeding 50 million yu.
This round of financing was exclusively invested by Linghang New Territori.
The proceeds from this financing will be used to promote the research and development and clinical trials of the company's tumor immunotherapy platform pipeline, as well as the construction of other platform technologies, while further improving the research and development team and expanding the research and development si.
In addition, Mozhuo Biological recently announced the completion of the A+ round of financing of nearly 100 million yu.
The funds raised in this round of financing will be mainly used to further expand the company's single-cell product research and development pipeli.
Since the beginning of this year, successful cases of investment and financing of pharmaceutical companies have continued to emerge in the indust.
According to incomplete statistics, there have been 161 cumulative investment and financing events on the innovative drug track in the first half of the ye.
Among them, 34 financing events focused on cell therapy, and 14 financing events exceeded 100 million yu.
Regarding the financing wave of innovative drug companies, the industry believes that this is mainly because most of the core products of innovative drug companies are still in the clinical or even preclinical research and development stage, and most of them have not yet formed a sizable and stable source of income, and need to obtain continuous cash through primary and secondary market financi.
due to fl.
In the past two years, the rapid influx of global funds into the biopharmaceutical industry has driven the sharp rise in the stock prices of pharmaceutical companies, and also led to continued active investment and financing activities in this fie.
Among them, it is worth noting that, from the perspective of innovative drugs, cell and gene therapy has clearly become a popular segment for investme.
However, it should be noted that although the investment opportunities in the field of medicine and health are still favored by the industry as a whole, the timing of the opening of the next financing window is still full of uncertainty, and many companies have begun to cut costs and put more Focus more on mature pipelin.
For example, Clover Bio will reduce its investment in non-COVID-19 related mid-to-late projects and new infrastructure in order to allocate resources to certain projec.
SCB313 (TRAIL trimer tumor project), SCB-808, SCB-420 (Fc fusion protein ) inputs to three projects have also been suspend.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
